Biotest Pharma Gmbh

Other

Wolfgang Moller

Wolfgang Stephan

Dieter Rudnick

Detlef Piechaczek

Michael Kraus

Norbert Kothe

Herbert Dichtelmuller

Reinhard Lissner

Henry Hies

Ronald Kotitschke

Hans Schleussner

Michael Kloft

Bertram Eichentopf

Ulf Bethke

Helge Karch

Gunter Sprotte

Hebert Dichtelmuller

Dietrich Nitsche

The invention concerns the oral administration of immunoglobulins from plasma, colostral milk, milk, eggs or cell cultures for the therapy and prophylaxis of heavy therapy-refractory pain conditions in patients without typical pathological anatomical correlates.

Oral administration of immunoglobulin preparations for treatment of

The invention relates to the use of colostral milk or colostral milk preparations from the cow, or fractions containing immunoglobulin prepared therefrom, as a liver protective preparation for the prevention and treatment of liver function disturbances in liver diseases, especially for the prevention of the sequelae of these diseases, such as portal encephalopathy.

Use of bovine colostral milk as a preparation for the protection of the

The present invention relates to a process for obtaining sterile milk, wherein the calcium ion content is reduced preferably to half of the naturally occurring amount by means, for example, of ion exchange or dialysis, and the milk is then filtered sterile, and if desired calcium ions are added again to restore the natural content. The product thus obtained has all of the biological activities as well as virtually the original composition, but it is free of bacteria, fungi and spores and will keep for a longer time.

Process for the sterile filtration of milk

Intravenously administered chemically unmodified immunoglobulin preparation containing more than 5% of its total immunoglobulin by weight consisting of IgM and/or more than 10% of its total immunoglobulin of IgA and with a low anticomplementary activity, and method of preparing it by anion-exchange chromatography.

Unmodified intravenously administered immunoglobulin preparations

An intravenously administrable polyclonal immunoglobulin preparation for the treatment and prophylaxis of bacterial infections containing at least 50% by weight of IgM in terms of the total content of immunoglobulin, exhibiting a low anticomplementary activity, being stable in aqueous solution, and being free of viruses. It can also consist of or also contain a mixture of several monoclonal IgM antibodies. The source material for its manufacture is an immunoglobulin-containing fraction of human, animal, or bacterial provenance. The fraction is treated with an anion exchanger that is eluted with a saline or pH gradient and the eluate is optionally subjected to gel filtration, treated before or after the chromatography with .beta.-propiolactone and PEG 4000, and optionally heated. Treatment with .beta.-propiolactone and ultraviolet light, treatment with solvents and detergents, or pasteurization can also be conducted. Proteins, sugars, or mixtures of amino acids are optionally added to the preparation.

Intravenously administerable polyclonal immunoglobulin preparation

A sterile-filtered colostrum solution that contains casein is made by adjusting the pH of a colostrum solution to 2.5 to 3.5 and then filtering it clear and sterile. It is preferably first defatted, and adjusted to pH 5.5 to 8 after the acid treatment but before being filtered.

Colostrum filtered sterile

A method of producing thrombin from Factor II (prothrombin) comprising the steps of:

Method of producing thrombin from factor II using calcium ions for the

Process for the preparation of an immunoglobulin solution suitable for intravenous administration from a human blood protein fraction containing immunoglobulins IgG, IgA and IgM in partially concentrated from, with the process steps: addition of acetate buffer to the protein fraction, where appropriate removal of insoluble constituents by filtration, treatment with calcium phosphate and octanoic acid, centrifugation, removal of the supernatant and treatment thereof with an adsorbent, removal of the adsorbent and sterilization by filtration.

Process for the preparation of a pharmaceutical which contains IgG, IgA

A method of enrichment of coagulation Factors II, VII, IX and X in preparations obtained from plasma, plasma fractions, or other liquids containing the factors, by adsorbing the factor or factors onto a polymeric matrix that carries an .alpha.-hydroxylamine group, and eluting the factors. When the chromatography conditions are appropriate, it is also easy to prepare a highly concentrated Factor IX preparation with a purity of more than 10 U per mg of protein.

Method of enrichment of coagulation factors II, VII, IX and X

A method of isolating blood-clotting Factor IX. A solution containing the Factor IX is adsorbed onto an adsorbent carrying .alpha.-hydroxylamine groups, and the factor is eluted. The Factor IX from the eluate is adsorbed onto a matrix carrying sulfated carbohydrates, with the conductivity adjusted to 13-17 mS/cm, and eluted with a salt gradient. The pure Factor IX is concentrated and freeze-dried.

Method of isolating blood-clotting factor IX

To provide a simple method of preparing biologically active transferrin that can be employed on an industrial scale and that will result in extremely pure and natural transferrin containing no viruses and appropriate for both in-vitro and in-vivo applications, the .gamma.-globulins are precipitated from the fraction containing the transferrin, the precipitant is removed from the residual liquid by ultrafiltration or gel filtration, the liquid is adjusted to a prescribed ionic concentration and protein concentration and (a) treated with .beta.-propiolactone and the solution is subjected to ultraviolet radiation or (b) treated with specific detergents and subjected to ion-exchange chromatography, and the transferrin is concentrated and filtered sterile.

Method of preparing a high-purity, virus safe, biologically active

A method of sterilizing plasma or plasma fractions, including fractions that contain the blood-coagulating Factor VIII by treatment with .beta.-propiolactone or ultraviolet radiation. Treatment with tri-n-butyl phosphate and sodium cholate or Tween 80 is carried out either prior to or simultaneously with the .beta.-propiolactone treatment or ultraviolet radiation.

Growing community of inventors

Oberursel, Germany

Wolfgang Moller